Baylor Health Care SystemAbout B
Research: From moving better to recovering faster, here's what we're studying. 
Need something? Call us: 1.800.4BAYLOR(1.800.422.9567)
Text Size:

Research Studies 

Find the trial that interests you in 3 easy steps.

Step 1: Please choose a condition.

Step 2: Select the appropriate diagnosis from the list below. You will then be presented with a listing of the clinical trials taking place at Baylor.

Step 3: Optionally, select a facility.

  • Prospective Cohort Study of BRCA1 and BRCA2 Mutation Carriers and Non-Carriers with Compelling Family History (UPENN PROSE study)
  • Risk Factor Analysis of Hereditary Breast and Ovarian Cancer
  • A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients With Metastatic Breast Cancer
  • The BEACON Study (Breast Cancer Outcomes With NKTR-102)
  • Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
  • Phase II Multicenter Single-arm Study of BKM120 Plus Capecitabine for Triple Negative Breast Cancer (TNBC) Patients With Brain Metastases
  • A Phase II Randomized, Double-blind Placebo Controlled, Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor-positive HER2-negative Breast Cancer
  • An Observational Cohort Study Of Treatment Patterns And Outcomes In Patients With HER2 Positive (Her2+) Metastatic Breast Cancer (SystHERs Registry (Systematic Therapies for HER2+ Metastatic Breast Cancer Study).
  • COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
  • A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
  • Pilot Safety Trial of Anakinra Combined With Chemotherapy and Dendritic Cell Vaccine in Patients With Locally Advanced, Triple-Negative Breast Cancer
  • Scalp Cooling for Alopecia Prevention (SCALP)
  • Pilot Safety and Blood Immune Cell Transcriptional Profiling Study of Anakinra plus The Physician’s Chemotherapy Choice in Metastatic Breast Cancer Patients
  • Collection of Patients' Tumor Tissue For Analysis Of Molecular Markers That Predict For Benefit From Cancer Therapies
  • Effect of Exercise during Adjuvant Chemotherapy Infusion for Breast Cancer
  • A Randomized, Double-blind, Placebo Controlled, Phase II/III Study of BKM120 Plus Paclitaxel in Patients With HER2 Negative Inoperable Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Pathway Activation.
  • Phase I/Prospective Randomized Phase II Trial Of the Safety and Efficacy of Tamoxifen in Combination With GDC-0032 Compared With Tamoxifen alONe.
  • A Phase Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0032 in Combination With Either Docetaxel or Paclitaxel in Patients With HER2-Negative, Locally Advanced or Metastatic Breast Cancer
  • Evaluation of Miracle Mouthwash (MMW) Plus Hydrocortisone and Prednisolone Mouth Rinse as Prophylaxis for Everolimus -Associated Stomatitis
  • A Phase Ib/II Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
  • A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 With Letrozole in Adult Patients With Advanced ER+ Breast Cancer
  • A Phase 1b Study of LY2835219 in Combination With Endocrine Therapies for Patients With Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
  • A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Breast Cancer
  • A Randomized, Multicenter, Open Label Study of MM-302 plus Trastuzumab vs. Chemotherapy of Physician’s Choice plus Trastuzumab in Anthracycline Naive Patients with Locally Advanced/Metastatic HER2-Positive Breast Cancer
  • Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer
  • Pilot Safety and Blood Immune Cell Transcriptional Profiling Study of Anakinra Plus the Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients